{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:30:45Z","timestamp":1790206245063,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.antiviral.2016.05.013","type":"journal-article","created":{"date-parts":[[2016,5,22]],"date-time":"2016-05-22T09:19:04Z","timestamp":1463908744000},"page":"59-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Impact of elvitegravir on human adipocytes: Alterations in differentiation, gene expression and release of adipokines and cytokines"],"prefix":"10.1016","volume":"132","author":[{"given":"Ricardo","family":"Moure","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Gallego-Escuredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Villarroya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria del Mar","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan C.","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Villarroya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2016.05.013_bib1","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/MOL.0b013e32814e6d29","article-title":"Plasminogen activator inhibitor-1, adipose tissue and insulin resistance","volume":"18","author":"Alessi","year":"2007","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.antiviral.2016.05.013_bib2","doi-asserted-by":"crossref","first-page":"E336","DOI":"10.1152\/ajpendo.00272.2007","article-title":"A\u00a0central role for hepatocyte growth factor in adipose tissue angiogenesis","volume":"294","author":"Bell","year":"2008","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.antiviral.2016.05.013_bib3","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1517\/14656566.2015.1044436","article-title":"HIV integrase inhibitors: a new era in the treatment of HIV","volume":"16","author":"Blanco","year":"2015","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.antiviral.2016.05.013_bib4","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1055\/s-2007-978682","article-title":"Interleukin-8 production in human adipose tissue. Inhibitory effects of anti-diabetic compounds, the thiazolidinedione ciglitazone and the biguanide metformin","volume":"32","author":"Bruun","year":"2000","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.antiviral.2016.05.013_bib5","first-page":"1267","article-title":"Regulation of interleukin 8 production and gene expression in human adipose tissue in\u00a0vitro","volume":"86","author":"Bruun","year":"2001","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.antiviral.2016.05.013_bib6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/EJE-06-0716","article-title":"Circulating nerve growth factor levels in relation to obesity and the metabolic syndrome in women","volume":"157","author":"Bull\u00f3","year":"2007","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.antiviral.2016.05.013_bib7","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1097\/QAD.0b013e328345766f","article-title":"Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate for the initial treatment of HIV infection","volume":"25","author":"Cohen","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2016.05.013_bib8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.antiviral.2011.04.018","article-title":"Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines","volume":"91","author":"D\u00edaz-Delf\u00edn","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.05.013_bib9","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1128\/AAC.00104-12","article-title":"Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines","volume":"56","author":"D\u00edaz-Delf\u00edn","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.05.013_bib10","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1097\/00002030-200212060-00006","article-title":"HIV and antiretroviral drug distribution in plasma and fat tissue of HIV-infected patients with lipodystrophy","volume":"16","author":"Dupin","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2016.05.013_bib11","doi-asserted-by":"crossref","first-page":"15130","DOI":"10.1074\/jbc.M312875200","article-title":"In\u00a0vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes","volume":"279","author":"El Hadri","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.antiviral.2016.05.013_bib12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2174\/157016210793499222","article-title":"Differential effects of efavirenz and lopinavir\/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines","volume":"8","author":"Gallego-Escuredo","year":"2010","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.antiviral.2016.05.013_bib13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1468-1293.2008.00636.x","article-title":"British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy","volume":"9","author":"Gazzard","year":"2008","journal-title":"HIV Med."},{"key":"10.1016\/j.antiviral.2016.05.013_bib14","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.beem.2010.12.001","article-title":"Adipose tissue biology and HIV-infection","volume":"25","author":"Giralt","year":"2011","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.antiviral.2016.05.013_bib15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jama.300.5.555","article-title":"Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-U.S.A. panel","volume":"300","author":"Hammer","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2016.05.013_bib16","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/QAD.0b013e32832b4377","article-title":"Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment","volume":"23","author":"Haubrich","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2016.05.013_bib17","doi-asserted-by":"crossref","first-page":"E1072","DOI":"10.1152\/ajpendo.00206.2003","article-title":"Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels","volume":"285","author":"Lihn","year":"2003","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.antiviral.2016.05.013_bib18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10156-010-0101-5","article-title":"Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir","volume":"17","author":"Minami","year":"2011","journal-title":"J.\u00a0Infect. Chemother."},{"key":"10.1016\/j.antiviral.2016.05.013_bib19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2174\/157016211795945278","article-title":"Neutral actions of Raltegravir on adipogenesis, glucose metabolism and lipolysis in 3T3-L1adipocytes","volume":"9","author":"P\u00e9rez-Matute","year":"2011","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.antiviral.2016.05.013_bib20","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/jac\/dkn191","article-title":"The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy","volume":"62","author":"P\u00e9rez-Molina","year":"2008","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2016.05.013_bib21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/11584570-000000000-00000","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir","volume":"50","author":"Ramanathan","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.antiviral.2016.05.013_bib22","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa074609","article-title":"Class-sparing regimens for initial treatment of HIV-1 infection","volume":"358","author":"Riddler","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2016.05.013_bib23","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/QAI.0b013e318286415c","article-title":"A\u00a0randomized, double-blind comparison of coformulated elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results","volume":"62","author":"Rockstroh","year":"2013","journal-title":"J.\u00a0Acquir. Immune. Defic. Syndr."},{"key":"10.1016\/j.antiviral.2016.05.013_bib24","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"Sax","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2016.05.013_bib25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.ijo.0802068","article-title":"The chlorophyll-derived metabolite phytanic acid induces white adipocyte differentiation","volume":"26","author":"Schl\u00fcter","year":"2002","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"10.1016\/j.antiviral.2016.05.013_bib26","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1128\/AAC.00712-13","article-title":"Evaluation of the effect of cobicistat on the in\u00a0vitro renal transport and cytotoxicity potential of tenofovir","volume":"57","author":"Stray","year":"2013","journal-title":"Antimicrob. Agents. Chemother."},{"key":"10.1016\/j.antiviral.2016.05.013_bib27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/sj.ijo.0801520","article-title":"Characterization of a human preadipocyte cell strain with high capacity for adipose differentiation","volume":"25","author":"Wabitsch","year":"2001","journal-title":"Int. J. Obes. Relat. Metab. Disord."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216302832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216302832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T18:26:14Z","timestamp":1536690374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354216302832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":27,"alternative-id":["S0166354216302832"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.05.013","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of elvitegravir on human adipocytes: Alterations in differentiation, gene expression and release of adipokines and cytokines","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}